Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma-Reference-Cited by-同舟云学术

Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma

Published:2023-02 Issue: Volume:188 Page:106656
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Peng Yan,Zhang Wenqing,Chen Yufeng,Zhang Louqian,Shen Hongyu,Wang Zheyue,Tian Shuning,Yang Xiaohui,Cui Daixun,He Yiting,Chang Xinxia,Feng Zhenqing,Tang Qi,Mao Yuan

Publisher

Elsevier BV

Subject

Pharmacology

Reference56 articles.

1. Cancer Statistics, 2021;Siegel;CA Cancer J. Clin.,2021

2. Lung cancer: current therapies and new targeted treatments;Hirsch;Lancet,2017

3. A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mphi polarization in TME;Xiao;Pharmacol. Res.,2022

4. Immune checkpoint blockade in cancer therapy;Postow;J. Clin. Oncol.,2015

5. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer;Kumar;Curr. Probl. Cancer,2017

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment;International Journal of Molecular Sciences;2024-08-22

2. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy;Journal of Translational Medicine;2024-08-05

3. Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells;International Immunopharmacology;2024-07

4. Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?;Frontiers in Oncology;2024-05-28

5. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review;Frontiers in Immunology;2024-04-17